Wockhardt’s Strategic Exit from US Generic Business

Wockhardt has announced its decision to exit its loss-making US generic pharmaceutical business as part of a strategic realignment aimed at focusing on innovation in antibiotics and biological drugs for diabetes. The company's US subsidiaries, Morton Grove Pharmaceuticals and Wockhardt USA LLC, have been filed for voluntary liquidation under Chapter 7 of the US Bankruptcy Code. The move follows years of losses, with the US generic segment reporting a USD 8 million loss in FY2025. By exiting this commoditised segment, Wockhardt aims to redirect resources and focus on high-impact areas like new antibiotic development and advanced insulin therapies. This strategic shift aligns with the company’s vision to become an innovation-driven pharmaceutical enterprise. Wockhardt remains committed to its operations in India, the UK, Ireland, and other key markets where it continues to deliver strong performance.